This study is looking at obesity, which is a condition where a person has excess body weight that may affect their health. The treatment being tested is a combination medicine called cagrilintide semaglutide, which contains two active substances called cagrilintide and semaglutide. The medicine is given as a solution for injection under the skin once a week. Some people in the study will receive placebo instead of the active medicine. The study will test two different dose strengths of the combination medicine.
The purpose of the study is to see how well the combination medicine helps people with excess body weight lose weight compared to placebo, when used together with eating fewer calories and doing more physical activity. The study will look at how much body weight people lose and how many people achieve certain weight loss goals.
People taking part in the study will receive weekly injections under the skin for a treatment period that can last up to several weeks. During the study, different measurements will be taken to see how the treatment is working, including body weight, waist size, blood pressure, and various blood fat levels such as cholesterol and triglycerides. The study will compare the results between people who receive the active medicine and those who receive placebo.
France 
Germany 
